**NOVARTIS AG** Form 4 May 29, 2009

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

(Print or Type Responses)

1. Name and Address of Reporting Person \*

**NOVARTIS AG** 

LICHSTRASSE 35

2. Issuer Name and Ticker or Trading

Symbol

**IDENIX PHARMACEUTICALS** INC [IDIX]

(Last) (First) (Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 05/29/2009

(Street)

(State)

4. If Amendment, Date Original

Filed(Month/Day/Year)

3.

5. Relationship of Reporting Person(s) to

**OMB** 

Number:

Expires:

response...

Estimated average

burden hours per

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

Issuer

(Check all applicable)

Director 10% Owner Officer (give title \_\_X\_ Other (specify

below) below)

6. Individual or Joint/Group Filing(Check

**INDIRECT 10% OWNER** 

Applicable Line)

Form filed by One Reporting Person X\_ Form filed by More than One Reporting

(D) or

Indirect (I)

(Instr. 4)

Person

**BASEL, V8 CH 4002** 

(City)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

4. Securities Acquired 5. Amount of

Price

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) any (Month/Day/Year)

Transaction(A) or Disposed of Code (D) (Instr. 8)

Code V Amount

(Instr. 3, 4 and 5)

(A)

or

(D)

Owned Following Reported

Securities

Beneficially

Transaction(s) (Instr. 3 and 4)

Common 05/29/2009 Stock

P 2,451 2.62

31,317,393

See footnote (1)

Beneficial

Ownership

(Instr. 4)

6. Ownership 7. Nature of

Form: Direct Indirect

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: NOVARTIS AG - Form 4

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title an	d 8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionNumber		Expiration D	ate	Amount of	of Derivative	e Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underlyin	g Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securities	(Instr. 5)	Bene
	Derivative			Securities			(Instr. 3 ar	nd 4)	Owne	
	Security				Acquired					Follo
	•				(A) or					Repo
					Disposed					Trans
					of (D)					(Instr
					(Instr. 3,					
					4, and 5)					
								Λ	nount	
									lount	
						Date Expiration	Or Title Nove	no la cu		
						Exercisable	Date	Title Number	mber	
				C 1 W	(A) (D)			of		
				Code V	(A) (D)			Sha	ares	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships
Reporting Owner Maine / Address	

Director 10% Owner Officer Other

**NOVARTIS AG** 

LICHSTRASSE 35 INDIRECT 10% OWNER

BASEL, V8 CH 4002

**NOVARTIS PHARMA AG** 

LICHSTRASSE 35 X 10% OWNER

**BASEL, V8 CH 4002** 

## **Signatures**

Jurgen Vierkotter, Authorized Signatory 05/29/2009

\*\*Signature of Reporting Person Date

Ramon Zapata-Gomez, Head Finance

Operations 05/29/2009

\*\*Signature of Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Date

Reporting Owners 2